Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease.
Tumour necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine with various roles in inflammatory processes. Several TNF blockers are currently approved for use in rheumatoid arthritis (RA) as well as in other inflammatory arthropathies. The latest of these compounds is the human monoclonal antibody, adalimumab, which was obtained using phage display technology and successfully produced in a mammalian expression system. Clinical application of this compound led to significant improvement in patients suffering from RA, both as monotherapy and in combination with various disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX). Moreover, radiographic progression is significantly inhibited and quality of life improved. This article summarises the available information.
Machold
Klaus P
KP
Department of Internal Medicine 3, Vienna University, Währinger Gürtel 18-20, A-1090 Vienna, Austria. klaus.machold@akh-wien.ac.at
Smolen
Josef S
JS
D000068879:Adalimumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001168:Arthritis / Q000628:therapy*; D001172:Arthritis, Rheumatoid / Q000628:therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab